Form 8-K - Current report:
SEC Accession No. 0001104659-25-002278
Filing Date
2025-01-10
Accepted
2025-01-10 07:00:25
Documents
15
Period of Report
2025-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 2.06: Material Impairments
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm252728d1_8k.htm   iXBRL 8-K 51395
2 EXHIBIT 99.1 tm252728d1_ex99-1.htm EX-99.1 33689
6 GRAPHIC tm252728d1_ex99-1img001.jpg GRAPHIC 3269
  Complete submission text file 0001104659-25-002278.txt   280594

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pasg-20250108.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pasg-20250108_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pasg-20250108_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT tm252728d1_8k_htm.xml XML 3826
Mailing Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103
Business Address ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103 2678660312
Passage BIO, Inc. (Filer) CIK: 0001787297 (see all company filings)

EIN.: 822729751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39231 | Film No.: 25520340
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)